Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Thoratec  (Stock symbol: THOR ) Acquired by St. Jude Medical (2015 $ 3,400,000,000)

6035 Stoneridge Drive
Pleasanton, CA 94588
Website Company Summary Management Team

Outside board: (May no longer be on the board) Don Hill (University of California, San Francisco Vice Chairman) Paul A LaViolette (SV Life Sciences Advisors Venture Partner) Howard Chase (The Hollandbrook Group President);  J Daniel Cole (Spray Venture Fund General Partner);  Stephen H Collis (AmerisourceBergen EVP);  Keith Grossman (TPG Biotech Managing Director) Daniel M Mulvena (Commodore Associates Principal);  William Hawkins (Immucor CEO);  Todd Schermerhorn (C.R. Bard Former CFO);  Elisa Finney (Varian Medical Systems CFO) Neil F Dimick (AmeriSource Bergen Brunswig)
Former outside board: Theo Melas-Kyriazi (Thermo Electron Corporation)

Business description: Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate II® and HeartMate III™ LVAS (Left Ventricular Assist Systems) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag®, PediMag®/PediVAS®, and HeartMate PHP™ product lines. HeartMate III is an investigational device and is limited by US law to investigational use. HeartMate PHP is currently in development and not approved for sale. Thoratec is headquartered in Pleasanton, California

Ownership: Acquired by St. Jude Medical (2015 $ 3,400,000,000)
Stock Symbol: THOR

Last Tweets


Last Mentions

Record updated: Sep 2014
Sector: Medical
Year Founded: 1976
Headcount: 601-700 as of Jun 2011
Ownership: Acquired by St. Jude Medical (2015 $ 3,400,000,000)
Stock Symbol: THOR